Oxford Cannabinoid Technologies Holdings plc (“OCTP” or “the Company”), the holding company of Oxford Cannabinoid Technologies Ltd (“OCT”) (together the “Group”), a pharmaceutical company developing prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the US$ multi-billion pain market, announces that its Annual Report and Accounts for the period ended 31 May 2021, Notice of Annual General Meeting ("AGM") and Form of Proxy (“Proxy”) have today been posted to shareholders. Also included with this communication is a deemed consent letter to allow shareholders to register their preference on how they wish to receive shareholder documentation in the future.
Each of these documents has been uploaded to the National Storage Mechanism and are available at: www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism.
Documents are also available on the Company's website at: https://www.oxcantech.com/investor-financial-results-centre and in hard copy to shareholders upon request to the Company Secretary at Maddox House, 1 Maddox Street, London W1S 2PZ.
As announced on 13 October 2021, the Company's AGM will be held at the offices of Penningtons Manches Cooper LLP at 125 Wood Street, London on 24 November 2021 at 10a.m.
Given the current circumstances in relation to COVID-19, the Board recommends shareholders not to attend the AGM in person and, instead, to exercise their votes by appointing the Chairman of the meeting as their proxy by returning a proxy form to: Computershare Investor Services PLC, The Pavilions, Bridgwater Road, Bristol BS99 6ZY so as to be received by 10:00 a.m. on 22 November 2021, or, in the event of an adjournment of the meeting, 48 hours before the adjourned meeting. Shareholders remain entitled to attend in person should they wish to do so. Further details are provided in the Notice of Annual General Meeting.
With the issues surrounding individual attendance at the AGM, the Company will this year be uploading onto its website a presentation to shareholders on the business of the Company and its recent performance. The presentation will not include any information which is not already in the public domain. The Company is aware that the AGM gives shareholders the opportunity to ask the Board questions and encourages shareholders to submit any such questions in advance via email to info@oxcantech.com and entitled ‘AGM 2021’. Answers to questions received will be uploaded onto the Company website following the AGM.
The Directors of the Company take responsibility for the contents of this announcement.
For further information, please contact:
Enquiries:
|
Oxford Cannabinoid Technologies Holdings plc
Dr John Lucas (CEO)
Clarissa Sowemimo-Coker (COO)
|
+44 (0)20 3034 2820
john@oxcantech.com
clarissa@oxcantech.com
|
|
Cairn Financial Advisers
Emily Staples
Jo Turner
|
+44 (0)20 7213 0897
+44 (0) 20 7213 0885
|
|
Walbrook PR Limited
Paul Vann
Nicholas Johnson
|
+44 (0)20 7933 8780
+44 (0)7768 807631
oxcantech@walbrookpr.com
|
About Oxford Cannabinoid Technologies Holdings Plc:
Oxford Cannabinoid Technologies Holdings plc (“OCTP”) is the holding company of Oxford Cannabinoid Technologies Ltd (“OCT”) (together the “Group”), a pharmaceutical company developing prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the U$ multi-billion pain market. Cannabinoids are compounds found in the cannabis plant that have been shown to have a range of therapeutic effects on the body, including pain relief. The Group has a clearly defined path to commercialisation, revenues and growth. The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence.
The Group’s portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities. The Group’s lead compound, OCT461201, is a highly potent and selective CB2 agonist and is being developed by OCT in a solid oral dosage form. OCT is conducting pre-clinical testing and development with pre-clinical trials scheduled for 2022. The Group’s product pipeline also uses a balanced drug product strategy that employs phytocannabinoids, cannabinoid derivatives and other novel compounds for the treatment of pain.
OCTP operates a partnership model with external academic and commercial partners, including the University of Oxford.